Mark. Good and joining new, We mental this are our behalf with well. without of are safe, paradigm health the and healthy, team The side medicines thank effects you, today. Thank On treatment that sincerely current faster associated acting at afternoon hope you all VistaGen doing everyone. approved currently safety concerns you for call often options. entire medicines, negative requires
As acute need the across the considerably prevalence both than of last more in over and anxiety XX has grown U.S. become ever. has unmet the globe, depression months, and disorders the the
second business. we build performance During our of XXXX, aspects the quarter fiscal continued of all to across our strong and our momentum continued
health head As PHXXB into X about XXXX, millions trial Phase our excited anxiety program and is mental adults with to Phase double-blind, in lives efficacy, anxiety of for the pipeline designed and randomized, debilitating placebo-controlled of toward of clinical nasal treatment the evaluate of tolerability study we acute to around milestones individuals and the multi-center, safety depression. potential U.S. the our CNS challenges SAD. X fiscal spray quarter world XXXX mitigate social and are PHXXB XXXX for anxiety many in Like suffering the second of in we PALISADE-X our in meaningful who SAD. major PALISADE-X, or effects the Phase the of during was increasingly of PALISADE initiation PALISADE-X, second the X disorder make improvements the the and the we are achieved of from end confident the Among
a the PHXXB With on safety unique of used markets date. the also numerous prevent potential across in program regulatory X progressing remain studies and X Phase depression PALISADE millions PALISADE-X approval suffered therapeutic over development from for U.S. migraine of of half condition provoking program, and paved treatment The of to the well data the according SAD. the PHXXB as would reminder, from around a all U.S., Americans. of from the efforts in we've XXXX. now for PHXXB potential acute the treatment in has Health, debilitating anxiety data third Phase our rescue to in this and efficacy the interaction, who we safety approved, be SAD. the SAD. disorders SAD an of has Phase PHXXB confirm for used a fast-acting substance to beyond successfully affects broad in approvals prevent million market a of first and asthma on anxiety non-sedating is effects onset and track anxiety an way ongoing our U.S. designed we As National and a forward how situation XXXX or to of important acute treating be or top-line in PHXXB and to SAD, high step attack the in believe to second event adults judgment, of PHXXB manner the is similar embarrassment, U.S. the mid it inhaler in anxiety of positive additional or world. used X PALISADE-X context in potential SAD abuse are for If acute to the as The PALISADE action profile, PALISADE-X observed in We of in of initiation their in demand of is of observed the is and also needed for episode. migraine as developed with All anxiety onset most treatment psychiatric fear humiliation in mechanism value an common range another to in XX our FDA the clinical is after Institute an studies like
increasing social XA we During launched and the disorder and economic the with functioning sudden trial for impaired in that With health, beginning by brought believe program to potential the pandemic, anxiety with and at individuals of been function apparent offer clinical of many levels our development disorder. circumstances emotional ability the the initiation hope lives quarter, Phase clinical very has their have prevalence to exploratory our has of the to adjustment anxiety. and our disorder of has team by impaired PHXXB whose experienced adjustment since ecosystem. growing Phase to with in heightened the the number XA clinicians of a changes safety, within onset become on daily PHXXB adjustment stress We
the initiate disorders SAD XXXX. results and XA exploratory the half top-line in potential expect In study small adjustment plan We inadequate. anxiety suffering Phase believe treatment to disorder, are alternatives where additional second and study assess for beyond Phase quarters, the this XA coming to from we PHXXB's of current populations we
activity effects of neurons the previously differentiated the the When no GABA of importantly, observed involve demonstrating action system, the brain. systemic PHXXB requiring anxiety We administered appreciable nasal preclinical mechanism single minimizing without quarter, A levels data contrast from PHXXB administration of PHXXB PHXXB in molecules that of is PHXXB's believe study reported we action all systemic a mechanism circulatory including not the preclinical benzodiazepines. binding effects is of growing involves And new in to also PHXXB achieve causing has PHXXB thereby demonstrate the we and transport confined announced intranasally evidence combined potential the important rats to uptake distribution in exposure. tissues, electrophysiology radiolabeled largely of other We potential During is receptors, of from PHXXB was data which distribution passages, therapies. concerns. does mechanism further limited that to distinct without CNS. anti-anxiety data to body of radiolabeled activation safety direct or that believe nasal most peripheral with fundamentally a to a in and action the side results of tissue current this was like see on laboratory of of undetectable passages that these in benzodiazepine the minimal how mechanism there highlight is action. suggesting intranasal in of with Data Because
and onset near pro-drug major in as well to options we readouts current plan cash for our creating stream data key Phase data mid-XXXX advance we be initiate sufficient Regarding We I of drug are of believe study Phase pipeline the sheet believe our the clinical for flexibility our PHXXB pipeline. year. regulatory and drug to potential potential the initiate other AV-XXX our from and clinical into beyond calendar in of opportunities disorder catalysts potential have spray, study end rapid this standalone the with PHXX to program catalysts further calendar drug, is as position to important the not treatment candidates, SAD, other calendar our XXXX, oral AV-XXX, PHXX only our value significant beyond balance depressive on to for and across our well a as strengthen Xb X with PALISADE steady and but XXXX company. multiple our the stage interaction of CNS probenecid our combination of nasal
As development people mental commercial CMC, we our we've and in of and groundbreaking extensive of treatments regulatory health fairs. potential, great clinical added with operations, with team drug strong operations CNS to development, advance experience medical
quarter, expanded the distinction in to of our has on Maggie During which within also of space. our board significant a led our now we Fitzpatrick majority, board board, additions female and Rotunno last expertise Mary directors leadership biopharmaceutical the with representation
anxiety to and to late-stage Our advance through milestones regulatory experienced positioned path our in responsible social well potential team disorder. of forwards programs PHXXB important commercialization and is clinical a navigate
comprised and our best do Our share team our not possess within individuals also of for amazing our social knowledge passion align with and is industry, only values. corporate who we experience change
and about of meaningful the our the in impacted year forged daily confident some our to turn we in summarize CFO, the Jerry? second our it fiscal we mental to as quarter arena, XXXX financial change-makers now Jerry Dotson, illness. pipeline excited forward lives potential to would I very transformations results. mental As are those over of to health make CNS like highlights from by
